Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3)
Christopher J Edwards(University Hospital Southampton NHS Foundation Trust), Paul Bird(UNSW Sydney), Jacob Aelion(Middle Tennessee Research Institute), Janusz Jaworski(NZOZ Centrum Alergologii), Jeffrey Crowley, Xiaojiang Zhan(Nanchang University), Adele R. Vessey(Bristol-Myers Squibb (Switzerland)), Randall M. Stevens, C. Birbara(University of Massachusetts Chan Medical School), Francisco J. Blanco(Complexo Hospitalario Universitario A Coruña)
Cited by 286
Related Papers
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update
|Annals of the Rheumatic Diseases|2020|2.8k
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update
|Annals of the Rheumatic Diseases|2022|1.9k
2022 update
|Radboud Repository (Radboud University)|2010|1.6k
EULAR recommendations for the use of imaging of the joints in the clinical management of rheumatoid arthritis
|Annals of the Rheumatic Diseases|2013|668